Gerard Platenburg - PROQR THERAPEUTICS Executive
| 0PQ Stock | EUR 1.88 0.01 0.53% |
Executive
Mr. Gerard Platenburg is a CoFounder, Chief Innovation Officer of ProQR Therapeutics NV. He served as the sole Member of the Company Supervisory Board between August 2012 and December 2013. He has more than twenty years of senior managerial experience, which he gained during his different operational and leadership roles in growing biotech companies. Prior to joining the Company, Mr. Platenburg worked at Isa Pharmaceuticals B.V. from June 2009 to January 2014. Mr. Platenburg cofounded Prosensa Holding N.V., growing it to become a wellknown RNA modulation clinical stage company, and held various positions between April 2002 and May 2009, including Chief Executive Officer and Chief Development Officer. Mr. Platenburg also worked at Pharming B.V. from April 1990 to March 2002. He is a passionate and driven pioneer of early stage technologies
| Age | 49 |
| Phone | 31 88 166 7000 |
| Web | http://www.proqr.com |
PROQR THERAPEUTICS Management Efficiency
The company has return on total asset (ROA) of (0.2628) % which means that it has lost $0.2628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7451) %, meaning that it generated substantial loss on money invested by shareholders. PROQR THERAPEUTICS's management efficiency ratios could be used to measure how well PROQR THERAPEUTICS manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 |
PROQR THERAPEUTICS Leadership Team
Elected by the shareholders, the PROQR THERAPEUTICS's board of directors comprises two types of representatives: PROQR THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PROQR. The board's role is to monitor PROQR THERAPEUTICS's management team and ensure that shareholders' interests are well served. PROQR THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PROQR THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Boer, Chairman of the Management Board, Chief Executive Officer | ||
| Tiffany Burt, Vice President Head - Commercial | ||
| Rene Beukema, Chief Corporate Development Officer and General Counsel | ||
| David Rodman, Chief Development Strategy Officer, Member of the Management Team | ||
| Alison Lawton, Independent Member of the Supervisory Board | ||
| Gerard Platenburg, Chief Innovation Officer, Member of the Management Team | ||
| Noreen Henig, Chief Development Officer | ||
| Antoine Papiernik, Independent Member of the Supervisory Board | ||
| Dinko Valerio, Independent Chairman of the Supervisory Board | ||
| Aniz Girach, Chief Medical Officer | ||
| Naveed Shams, Chief Scientific Officer | ||
| Smital Shah, Chief Business and Financial Officer, Member of the Management Team | ||
| Theresa Heggie, Independent Member of the Supervisory Board | ||
| James Shannon, Independent Member of the Supervisory Board | ||
| Bart Filius, Independent Member of the Supervisory Board |
PROQR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PROQR THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (16.95) % | |||
| Shares Outstanding | 71.43 M | |||
| Shares Owned By Insiders | 20.89 % | |||
| Shares Owned By Institutions | 41.47 % | |||
| Revenue | 3.93 M | |||
| Gross Profit | 2.4 M | |||
| EBITDA | (66 M) | |||
| Net Income | (46.56 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PROQR THERAPEUTICS in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PROQR THERAPEUTICS's short interest history, or implied volatility extrapolated from PROQR THERAPEUTICS options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in PROQR THERAPEUTICS EO 04. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for PROQR Stock analysis
When running PROQR THERAPEUTICS's price analysis, check to measure PROQR THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROQR THERAPEUTICS is operating at the current time. Most of PROQR THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of PROQR THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PROQR THERAPEUTICS's price. Additionally, you may evaluate how the addition of PROQR THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |